Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIAAF Rx: Pharmacist Prescribing for Stroke Prevention in AF
NCT03126214Phase 4Completed
- Sponsor
- University of Alberta
- Start
- Feb 2018
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Atrial fibrillation (AFib) and stroke (2 arms), sponsored by University of Alberta. Primary endpoint: Optimal Oral Anticoagulant Therapy for Atrial Fibrillation Stroke Prevention at 3 months. Started Feb 2018; status: completed.
02
Conditions
Atrial fibrillation (AFib)stroke
Beyond the preview
Go deeper on NCT03126214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126214.